Incremental diagnostic and prognostic value of device interrogation in left bundle branch area pacing

Q: Does pacemaker interrogation add anything beyond symptoms and a 12-lead ECG in LBBAP?

Yes, and the reason is specific to conduction system pacing. An LBBAP lead has two capture thresholds — left bundle branch capture and left ventricular septal myocardial capture — and the myocardial threshold is usually the lower of the two. When the conduction system threshold rises above the programmed output, the patient does not lose capture; they convert silently to deep septal myocardial pacing at the same rate, with no bradycardia, no syncope and nothing to report at a symptom review. Diagnosis requires output-titrated threshold testing with a simultaneous 12-lead recording to demonstrate the nonselective-to-selective or septal capture transition, which needs the programmer and the electrodes in the same room. Lead impedance is also not a passive parameter in LBBAP: because the lead traverses the interventricular septum, a fall in unipolar impedance is the principal electrical marker of perforation into the left ventricular cavity, and unipolar impedance below 450 ohms identified septal perforation with 100% sensitivity and 96.6% specificity. Battery longevity is a dependent variable of programmed output, and accelerated depletion without a programming change is itself a lead-integrity signal. Interrogation additionally yields R-wave sensing trends, ventricular pacing percentage, atrial fibrillation burden and stored electrograms, none of which are visible on symptom review or a resting sinus-rhythm ECG.

Q: Why does a rise in LBBAP capture threshold not cause symptoms?

Because the lead is embedded deep in the interventricular septum, it captures myocardium at a lower output than it captures the left bundle branch. If the conduction system threshold rises above the programmed output, the myocardium is still captured at every beat. The rate is unchanged, there is no pause, no asystole and no presyncope. The patient reverts to deep septal myocardial pacing while feeling exactly the same. In one cohort, loss of left bundle branch capture occurred in 4.6% of patients during long-term follow-up, and only 1.5% required a redo procedure because the remaining patients retained an acceptable septal capture threshold below 1 V.

Q: Can a single 12-lead ECG detect loss of conduction system capture after LBBAP?

Not reliably on its own. The operational definitions used in the literature require both a change in paced morphology, such as loss of the terminal r or R wave in lead V1 and prolongation of the V6 R-wave peak time, and an inability to demonstrate output-dependent capture transition during threshold assessment. A resting ECG recorded at a single programmed output cannot demonstrate a transition, because a transition only appears when the output is stepped down. The ECG is the readout; the programmer supplies the stimulus. They are complementary rather than redundant.

Q: Is lead impedance actionable in left bundle branch area pacing?

Yes, more so than in right ventricular pacing. Because the helix is advanced through the septum, impedance reports tip position relative to the left ventricular cavity. Preclinical work found that progression from a deep septal to a perforated position produced an impedance fall of 583 plus or minus 305 ohms, a 23 to 69 percent drop. Clinically, a unipolar impedance below 450 ohms identified septal perforation with 100% sensitivity and 96.6% specificity. Delayed postoperative septal perforation occurs in roughly 0.08% to 0.33% of cases and can present with a rise in capture threshold or ventricular undersensing; overt perforation into the cavity requires lead revision because of thromboembolic risk and possible mitral valve damage. An unexplained impedance fall between visits in an asymptomatic patient is therefore a finding with a revision decision attached.

Q: Can automatic capture management be relied on to monitor LBBAP thresholds?

No. In left bundle branch pacing the difference between the conduction system capture threshold and the left ventricular septal capture threshold is usually less than 0.5 V, and automatic capture management algorithms track the lower myocardial threshold. The algorithm can therefore continue to report a stable, low, well-managed threshold trend after conduction system capture has already been lost. Only a manual, output-titrated threshold test correlated with a simultaneous 12-lead ECG can distinguish the two.

Conduction system pacing · Device follow-up

Does pacemaker interrogation add anything beyond symptoms and a 12-lead ECG in LBBAP?

The question on this page was put by Jesús Devesa, a human being who lives with a left bundle branch area pacing device. The analysis that follows was written by Claude.ai, Anthropic's AI assistant. Published on www.abcfarma.net · 16 August 2026.

The question as posed

In the context of left bundle branch area pacing (LBBAP), what is the incremental diagnostic and prognostic value of routine pacemaker interrogation beyond clinical symptom assessment and the 12-lead surface ECG, given that the three parameters uniquely obtained by interrogation are lead impedance, capture threshold and battery longevity, and that:

impedance is a non-actionable monitoring parameter;
battery depletion only informs elective replacement indicator (ERI) planning;
a clinically significant rise in capture threshold would presumably manifest with symptoms or loss of capture on the ECG?

Short answer

The syllogism is tight, but it rests on a premise that does not hold for LBBAP: that interrogation yields only three parameters, and that capture is binary. In conduction system pacing neither is true. An LBBAP lead has two capture thresholds, and the failure mode that matters most is precisely the one that is silent on symptoms and near-silent on a single-output ECG.

The premise problem: capture in LBBAP is not binary

A deep septal lead sits in myocardium and, if the implant succeeded, close enough to the left conduction system to capture it. That produces two distinct thresholds: left bundle branch (LBB) capture and left ventricular septal (LVS) myocardial capture. The myocardial threshold is usually the lower of the two.

The consequence is the crux of the whole question. When the conduction system threshold rises above the programmed output, the patient does not lose capture. They convert to deep septal myocardial pacing: same rate, same delivered beat, no bradycardia, no pause, no syncope, no presyncope, nothing whatsoever to report at a symptom review. Premise (c) fails here — in LBBAP, the clinically significant threshold rise is the one that produces no symptoms at all.

The reason to interrogate an LBBAP device is not to find out whether the lead still paces. It is to find out what it is still capturing.

How often this happens

Finding	Rate	Setting
Loss of LBB capture during long-term follow-up	4.6%	15 of 323 patients; only 1.5% required a redo procedure
Patients with lost LBB capture retaining an acceptable septal threshold	10 of 15	Septal capture threshold below 1 V — clinically and electrically unremarkable
Capture threshold rise, MELOS registry	0.7%	18 of 2,533 patients; 4 needed lead revision
Loss of conduction system capture without fluoroscopic displacement	6.1% / 3.0%	Stylet-driven vs lumenless leads; most within one month, one case at 340 days
New-onset LV dysfunction after LBBP	3.75%	16 of 426 patients over a mean 28.3 months

That group of ten patients — conduction system capture lost, septal threshold comfortably under 1 V, no revision performed — is the population this whole question is about. They look fine clinically. They look fine electrically. They have silently lost the physiologic rationale for the implant.

Why the ECG alone cannot close the gap

The published operational definitions make the dependency explicit. Loss of conduction system capture is defined as complete or partial loss of the right bundle branch delay pattern together with an inability to demonstrate output-dependent capture transition during threshold assessment. Loss of the terminal r or R wave in V1, and prolongation of the V6 R-wave peak time, are the morphological half of the criterion.

The other half cannot be obtained from a resting tracing. Demonstrating a nonselective-to-selective or nonselective-to-septal transition requires stepping the output down while recording twelve leads. That is a programmer manoeuvre with an ECG readout. Interrogation and the surface ECG are not two independent screening channels with overlapping yield; they are the stimulus and the recording arm of a single test.

The automatic capture management trap. Because the electrode is embedded deep in left ventricular myocardium, the difference between LBB capture and LV septal capture thresholds is usually under 0.5 V, and capture management algorithms are routinely enabled in these patients. The algorithm tracks and adapts to the myocardial threshold. It will keep reporting a flat, low, well-managed trend line long after conduction system capture has gone. A reassuring threshold graph is not evidence of conduction system capture.

Premise (a): impedance is not a non-actionable parameter in LBBAP

The claim that impedance is passive monitoring imports an assumption from right ventricular leads, where the tip sits on an endocardial surface and impedance mostly reports insulation and conductor integrity. An LBBAP lead is screwed through the interventricular septum. For that geometry, impedance is the principal electrical marker of tip position relative to the left ventricular cavity.

A unipolar impedance cutoff below 450 Ω identified septal perforation with 100% sensitivity and 96.6% specificity in a clinical series where perforation occurred during deployment in 14.1% of patients.
Preclinical work quantified the transition directly: advancing from a deep septal to a perforated position produced an impedance fall of 583 ± 305 Ω, a 23 to 69 percent drop.
Delayed postoperative septal perforation has an incidence of roughly 0.08% to 0.33%, usually within days to weeks, and can present with a rise in capture threshold and ventricular undersensing. Overt perforation into the cavity requires lead revision because of thromboembolic risk and possible mitral valve damage.

An impedance value that has fallen 200 Ω between two visits in an entirely asymptomatic patient is a finding with a revision decision attached to it. That is what actionable means. The trend matters more than the absolute number, which is exactly why the serial record kept by the device clinic has value that no single reading has.

Premise (b): battery longevity is a programming variable, not a calendar

Treating projected longevity as a passive readout misses that in LBBAP it is a dependent variable of the threshold you have just measured, and that the causal arrow runs in both directions.

When a lead revision is not judged necessary, the higher output required to maintain conduction system capture shortens battery life and brings forward the next generator change. Conversely, an unexpected acceleration of projected depletion in the absence of any programming change is itself a lead-integrity signal — the same signal an impedance shift would give, arriving through a different channel. And a substantial share of LBBAP recipients are pacemaker-dependent: implanted after AV nodal ablation, or for high-grade atrioventricular block. For them, ERI planning is not administrative scheduling. It is a safety-critical interval.

The parameter list in the question is incomplete

Impedance, threshold and longevity are the parameters a mental model built around is the lead working produces. A modern interrogation also returns:

R-wave amplitude and sensing trends — undersensing is a documented presentation of micro-dislodgement and of delayed septal perforation, and cannot be inferred from a surface ECG.
Ventricular pacing percentage — in a patient implanted for resynchronisation, a burden below the high nineties undermines the entire therapy while producing no distinctive symptom.
Atrial fibrillation and atrial tachycardia burden, with mode-switch logs — prognostically the heaviest item on the list, because it drives an anticoagulation decision with a stroke endpoint. Entirely invisible to symptom review and to a sinus-rhythm office ECG.
Stored electrograms for correlating an intermittent symptom with an actual rhythm, rather than with the rhythm that happens to be present in clinic.
Non-sustained ventricular tachycardia counters, rate histograms, lead noise and oversensing counts.

Where the argument does hold

A narrower version survives, and it is the useful one. For a non-dependent LBBAP patient several years out, with a documented stable capture transition and no arrhythmia history, the marginal yield of a routine in-person interrogation is genuinely low. That is precisely why remote monitoring is the guideline-endorsed default and why in-person attendance is best reserved for the things a remote transmission cannot do:

the output-titrated 12-lead capture transition test;
comparison of current paced QRS morphology against the implant baseline, including V1 terminal forces and V6 R-wave peak time;
manual threshold measurement where capture management cannot be trusted to discriminate the two capture types.

Reframing the question from is interrogation worth it to which components of follow-up are remote-eligible and which require a programmer and twelve electrodes in the same room is the productive form of the original thesis.

An honest limit on the prognostic half

The diagnostic case is strong. The prognostic case is currently inferential. Reviewers note that although long-term LBBAP threshold performance is reported as stable, whether the existing data accurately reflect ongoing capture of the left bundle remains unclear, and that larger prospective studies with careful assessment of paced QRS morphology in follow-up are needed.

The assumption that reverting to septal myocardial pacing carries the dyssynchrony risk the implant was meant to avoid is supported by mechanism, and by signals such as new-onset left ventricular dysfunction in 3.75% of LBBP patients with normal or recovered function over a mean of 28 months. It is not yet supported by a randomised comparison of surveillance strategies. Nobody has run a trial in which one arm receives output-titrated capture verification and the other does not.

Frequently asked questions

Why does a rise in LBBAP capture threshold not cause symptoms?

Because the lead captures myocardium at a lower output than it captures the left bundle. If the conduction system threshold rises past the programmed output, the myocardium is still captured on every beat. The rate is unchanged and there is no pause. The patient reverts to deep septal myocardial pacing while feeling exactly the same.

Can a single 12-lead ECG detect loss of conduction system capture?

Not reliably on its own. The morphological half of the criterion — loss of the terminal r or R in V1, prolonged V6 R-wave peak time — can be visible, but only against a known baseline, and the second half of the criterion requires demonstrating an output-dependent transition. A tracing recorded at one programmed output cannot show a transition.

Is lead impedance really actionable here?

Yes. For a lead traversing the septum, impedance reports tip position relative to the left ventricular cavity. A unipolar value below 450 Ω identified septal perforation with 100% sensitivity and 96.6% specificity, and overt perforation is a revision indication because of thromboembolic and mitral valve risk.

Can automatic capture management be relied on?

No. The gap between conduction system and septal capture thresholds is usually under 0.5 V, and the algorithm tracks the lower myocardial value. It can report a stable trend indefinitely after conduction system capture has been lost.

What is the single highest-yield item obtained only by interrogation?

For prognosis, device-detected atrial fibrillation burden, because it changes an anticoagulation decision with a stroke endpoint. For the LBBAP-specific question of whether the therapy is still doing what it was implanted to do, the output-titrated capture transition test.

Sources

Ponnusamy SS, et al. Loss of capture during long-term follow-up after left bundle branch pacing. JACC: Clinical Electrophysiology. 2023.
Jastrzębski M, et al. Left bundle branch area pacing outcomes: the multicentre European MELOS study. European Heart Journal. 2022;43:4161–4173.
De Pooter J, et al. Procedural outcome and follow-up of stylet-driven leads compared with lumenless leads for left bundle branch area pacing. EP Europace. 2023;25:euad295.
Ponnusamy SS, et al. Electrophysiological characteristics of septal perforation during left bundle branch pacing. Heart Rhythm. 2022;19:728–734.
Changes in lead parameters and septal morphology during left ventricular septal perforation: preclinical insights. JACC: Clinical Electrophysiology. 2022.
Perforation of the interventricular septum with left bundle branch area pacing: diagnosis and management. HeartRhythm Case Reports. 2024.
Failure of automatic capture management in left bundle branch pacing. Heart Rhythm. 2025.
New-onset left ventricular dysfunction after left bundle branch pacing. JACC: Clinical Electrophysiology. 2024.
Complications, troubleshooting and follow-up for left bundle branch area pacing. Arrhythmia & Electrophysiology Review. 2025.
Chung MK, Patton KK, Lau CP, et al. 2023 HRS/APHRS/LAHRS guideline on cardiac physiologic pacing for the avoidance and mitigation of heart failure. Heart Rhythm. 2023.

This page is educational content about cardiac electrophysiology and device follow-up. It is not medical advice, a diagnosis, or a treatment recommendation, and it does not describe the device behaviour of any individual patient. Programming changes, threshold testing protocols, follow-up intervals and any decision about lead revision must be made by the qualified cardiology or electrophysiology team responsible for your care. If you have an implanted device and are concerned about how it is functioning, contact your device clinic rather than acting on anything read here.